Skip to main content
Journal of Clinical and Experimental Hematopathology : JCEH logoLink to Journal of Clinical and Experimental Hematopathology : JCEH
. 2023 Dec 26;63(4):212–213. doi: 10.3960/jslrt.23051

Highlights: Follicular lymphoma

Recent advances of the pathobiology and treatment of follicular lymphoma and challenging to the new therapeutic avenues

Katsuyoshi Takata 1,
PMCID: PMC10861372  PMID: 38148010

Follicular lymphoma (FL) is the second most common B-cell lymphoma subtype in the world wide. Although around 85–90% of FL harbors t(14;18)/IGH-BCL2 translocation, this entity is clinically and genetically heterogenous from in situ lesion to advanced stage disease.1 Also, a part of FL transforms to aggressive lymphomas such as diffuse large B-cell lymphoma and rarely lymphoblastic lymphoma.2 Histologically, tumor follicles are characterized by containing abundant of tumor microenvironments such as follicular dendritic cells as well as T-follicular helper cell, T-regulatory cell, and vascular stromal cells.

Recent progress of genetic studies using next generation sequencing revealed genetic alterations as represented by EZH2, CREBBP, and MLL2 mutations in “common progenitor cells” in addition to BCL2 translocation.3,4 Moreover, several single cell studies are elucidating FL characteristics in the point of view of not only tumor cell heterogeneity but also the composition of tumor microenvironment.5,6

In this issue, we reviewed the recent advances of FL pathology, biology and therapies. Abe Y. describes “Follicular lymphoma microenvironment: insights provided by single-cell analysis” based on his unique approaches using single cell analysis.7,8 Carreas J. discusses “The pathobiology of follicular lymphoma” in terms of histopathological and genetic characteristics.9 Oishi N. explains “Precursory or early lesions of follicular lymphoma: clinical features, pathology, and genetics” especially in situ follicular neoplasms.10,11 Maeshima AM. discusses “Histologic transformation of follicular lymphoma: pathologist’s viewpoint”12 and Maruyama D. will discuss FL transformation at the point of view of clinical characteristics (in preparation). Finally, Fukuhara N. will describe the recent progress of FL treatment including epigenetic drugs (in preparation).

I believe this review series will let us understand the pathogenesis and behavior more accurately and handle it, that I hope it will lead to new therapeutic avenues for the patients.

REFERENCES

  • 1.Swerdlow SH, Campo E, Harris NL, et al. (eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, IARC. 2008. [Google Scholar]
  • 2.Geyer JT, Subramaniyam S, Jiang Y, et al. Lymphoblastic transformation of follicular lymphoma: a clinicopathologic and molecular analysis of 7 patients. Hum Pathol. 2015; 46: 260-271. [DOI] [PubMed] [Google Scholar]
  • 3.Okosun J, Bödör C, Wang J, et al. Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nat Genet. 2014; 46: 176-181. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Béguelin W, Teater M, Meydan C, et al. Mutant EZH2 Induces a Pre-malignant Lymphoma Niche by Reprogramming the Immune Response. Cancer Cell. 2020; 37: 655-673.e11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Wang X, Nissen M, Gracias D, et al. Single-cell profiling reveals a memory B cell-like subtype of follicular lymphoma with increased transformation risk. Nat Commun. 2022; 13: 6772. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Han G, Deng Q, Marques-Piubelli ML, et al. Follicular Lymphoma Microenvironment Characteristics Associated with Tumor Cell Mutations and MHC Class II Expression. Blood Cancer Discov. 2022; 3: 428-443. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Abe Y. Follicular lymphoma microenvironment: insights provided by single-cell analysis. J Clin Exp Hematop. 2023; 63: 143-151. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Abe Y, Sakata-Yanagimoto M, Fujisawa M, et al. A single-cell atlas of non-haematopoietic cells in human lymph nodes and lymphoma reveals a landscape of stromal remodelling. Nat Cell Biol. 2022; 24: 565-578. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Carreras J. The pathobiology of follicular lymphoma. J Clin Exp Hematop. 2023; 63: 152-163. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Oishi N, Segawa T, Miyake K, Mochizuki K, Kondo T. Incidence, clinicopathological features and genetics of in‐situ follicular neoplasia: a comprehensive screening study in a Japanese cohort. Histopathology. 2022; 80: 820-826. [DOI] [PubMed] [Google Scholar]
  • 11.Oishi N. Precursory or early lesions of follicular lymphoma: clinical features, pathology, and genetics. J Clin Exp Hematop. 2023; 63: 65-72. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Maeshima AM. Histologic transformation of follicular lymphoma: pathologists’ viewpoint. J Clin Exp Hematop. 2023; 63: 12-18. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical and Experimental Hematopathology : JCEH are provided here courtesy of Japanese Society for Lymphoreticular Tissue Research

RESOURCES